AbbVie to Invest $380M in AI-Powered API Plants; 111 Capital Slashes Stake 77%
AbbVie plans to invest $380 million to construct two AI-integrated active pharmaceutical ingredient manufacturing facilities at its Illinois campus beginning spring 2026 and online by 2029 as part of a $100 billion US R&D commitment. 111 Capital reduced its stake by 77.4%, selling 15,143 shares and retaining 4,411 shares valued at $1.02 million.
1. $380 Million Manufacturing Expansion
AbbVie announced a $380 million investment to build two state-of-the-art active pharmaceutical ingredient (API) manufacturing facilities at its Illinois campus. The new plants will integrate advanced manufacturing technologies with artificial intelligence to accelerate next-generation neurosciences and obesity drug development. Construction is set to begin in spring 2026, with both facilities expected online by 2029. This investment forms part of AbbVie’s broader $100 billion commitment to US research and development.
2. 111 Capital Reduces AbbVie Stake
111 Capital trimmed its AbbVie holding by 77.4% during the third quarter, selling 15,143 shares and leaving 4,411 shares valued at approximately $1.02 million. This significant reduction in position may reflect shifting institutional sentiment despite AbbVie’s long-term manufacturing and R&D expansion plans.